← Leaderboards
Jiyong Hong
Duke University
$5,518,476
Attributed
$11,086,990
Total exposure
11
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.6M · FY2009–25$5M$3.8M$2.5M$1.3M$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,086,990 · 11
By mechanism
R01$7,260,204 · 5
R61$1,563,778 · 1
R21$1,202,525 · 3
R56$669,233 · 1
R03$391,250 · 1
Top collaborators
- Seok-Yong Lee12 shared
- Pei Zhou5 shared
- Hendrik Luesch4 shared
- Jen-Tsan Ashley Chi1 shared
- Joseph Heitman1 shared
- Ru-Rong Ji1 shared
- William J Steinbach1 shared
- Ronald A. Venters1 shared
Most similar at Duke University
Same institution · by research overlap
- Seok-Yong Lee$17,896,850
- Pei Zhou$18,119,545
Others in their field
Top investigators on “Analog”
- David Heimbrook · Leidos Biomedical Research, Inc.$196,589,777
- Constance Ann Benson · University Of California, San Diego$84,289,569
- Norman Wolmark · Nsabp Foundation, Inc.$51,982,954
- Robert Turner Schooley · University Of Colorado Denver$48,513,949
- Kenneth A Bloom · University Of Nebraska-Lincoln$46,979,168
- John Hobbs · Suny At Stony Brook$41,239,084
Research focus
AnalogStructureDesignLeadIn VitroComplexMolecularExhibitsCellsBiologyMutagenesisInsightBindingBaseSignal TransductionPlaySpecificityIn VivoClinicAffectAgonistClinically RelevantInhibitor/AntagonistPharmaceutical Preparations
Grant awards (27)
LpxH Inhibitors as Novel Therapeutics Against Multidrug-resistant Enterobacterales$747,763
R01 · FY2025 · AI
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapy$521,760
R01 · FY2025 · CA · contact PI
TRPM8 in eye health and disease$471,291
R01 · FY2025 · EY
Developing equilibrative nucleoside transporter inhibitors as non-opioid pain therapeutics$1,563,778
R61 · FY2024 · NS
Inhibiting Rev1-mediated translesion DNA synthesis for cancer therapy$521,760
R01 · FY2024 · CA · contact PI
TRPM8 in eye health and disease$477,235
R01 · FY2024 · EY
TRPM8 in eye health and disease$409,999
R01 · FY2023 · EY
Molecular basis of adenosine transport and reuptake inhibition in human$406,553
R01 · FY2023 · GM
Development of MESH1 inhibitors to treat ferroptosis-associated neurodegeneration$427,817
R21 · FY2022 · AG · contact PI
Molecular basis of adenosine transport and reuptake inhibition in human$406,553
R01 · FY2022 · GM
TRPM8 in eye health and disease$397,697
R01 · FY2022 · EY
Molecular basis of adenosine transport and reuptake inhibition in human$406,553
R01 · FY2021 · GM
TRPM8 in eye health and disease$397,699
R01 · FY2021 · EY
Molecular basis of adenosine transport and reuptake inhibition in human$35,589
R01 · FY2021 · GM
Structural Biological Development of Fungal-Specific Calcineurin Inhibitors$669,233
R56 · FY2020 · AI
TRPM8 in eye health and disease$412,754
R01 · FY2020 · EY
Molecular basis of adenosine transport and reuptake inhibition in human$406,553
R01 · FY2020 · GM
Study of Subglutinol A as a Potential Immunomodulatory Agent$149,684
R21 · FY2018 · AI · contact PI
Study of Subglutinol A as a Potential Immunomodulatory Agent$264,904
R21 · FY2017 · AI · contact PI
Targeting Rev1-mediated Translesion Synthesis for Cancer Therapy$162,654
R21 · FY2016 · CA
Targeting Rev1-mediated Translesion Synthesis for Cancer Therapy$197,466
R21 · FY2015 · CA
Chemistry and Biology of Largazoles$299,580
R01 · FY2012 · CA
Chemistry and Biology of Largazoles$299,580
R01 · FY2011 · CA
Chemistry and Biology of Largazoles$313,844
R01 · FY2010 · CA
PKC zeta-Specific Inhibitors for Treatment of Methamphetamine Addiction$196,250
R03 · FY2010 · DA · contact PI
Chemistry and Biology of Largazoles$327,441
R01 · FY2009 · CA
PKC zeta-Specific Inhibitors for Treatment of Methamphetamine Addiction$195,000
R03 · FY2009 · DA · contact PI